Aclarion, Inc. (Nasdaq: ACON, ACONW) released a shareholder letter from CEO Brent Ness on March 19, 2026, detailing the company's strategic progress and key catalysts for 2026. The letter emphasizes Aclarion's focus on expanding adoption of its Nociscan platform, advancing reimbursement initiatives, and strengthening clinical evidence for its technology that helps physicians identify the location of chronic low back pain.
According to the letter, Aclarion is pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption. This initiative builds on the company's existing efforts in the United Kingdom and marks a critical milestone for commercial expansion. The company also expects an initial readout from its ongoing CLARITY clinical trial in the fourth quarter of 2026, which is designed to further validate the Nociscan platform's effectiveness.
Ness highlighted the company's strong balance sheet, noting a cash runway into 2028 that supports continued execution on these priorities. "Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business," said Ness. He added that increasing physician engagement and growing clinical evidence position Aclarion to advance its mission of building a scalable technology platform for chronic low back pain.
The Nociscan platform uses magnetic resonance spectroscopy (MRS) data from an MRI machine, processed through proprietary signal processing techniques and augmented intelligence algorithms, to help physicians distinguish between painful and nonpainful lumbar discs. This noninvasive SaaS platform provides critical insights into the location of low back pain, enabling optimized treatment strategies. The full CEO Shareholder Letter is available on the company's website.
For more news from Aclarion, visit the company's latest news page. Information on finding a Nociscan center is available via the company's site map here.
